Tamoxifen Reported to Cause Aggressive Cancer Tumors

Friday, August 28, 2009 by: Melanie Grimes
Tags: Tamoxifen, health news, Natural News

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
CDC issues flu vaccine apology: this year's vaccine doesn't work!
The five biggest lies about Ebola being pushed by government and mass media
Ultraviolet light robot kills Ebola in two minutes; why doesn't every hospital have one of these?
Tetanus vaccines found spiked with sterilization chemical to carry out race-based genocide against Africans
Biologist explains how marijuana causes tumor cells to commit suicide
Companies begin planting microchips under employees' skin
The best way to help your body protect itself against Ebola (or any virus or bacteria)
NJ cops bust teenagers shoveling snow without a permit
Russia throws down the gauntlet: energy supply to Europe cut off; petrodollar abandoned as currency war escalates
McDonald's in global profit free fall as people everywhere increasingly reject chemically-altered toxic fast food
W.H.O. contradicts CDC, admits Ebola can spread via coughing, sneezing and by touching contaminated surfaces
Top ten things you need to do NOW to protect yourself from an uncontrolled Ebola outbreak
Chemotherapy kills cancer patients faster than no treatment at all
FDA targets Dr. Bronner's Magic Soaps for sharing health benefits of coconut oil
U2's Bono partners with Monsanto to destroy African agriculture with GMOs
Why flu shots are the greatest medical fraud in history
Governments seize colloidal silver being used to treat Ebola patients, says advocate
Flu vaccine kills 13 in Italy; death toll rises

(NaturalNews) The cancer prevention drug, tamoxifen, may cause cancer. It has been reported that rare cancers are being found in long-term users. Tamoxifen is the drug of choice, prescribed after breast cancer detection or surgery. Its use is deemed to have a 20% success rate in preventing further incidences of cancer. For this reason, many breast cancer survivors are long term users of tamoxifen, and this news is disturbing for both them and their caregivers.

Tamoxifen is an estrogen-blocking drug. The tumors that developed in the tamoxifen users were rare but aggressive. Some suggest that the risks still outweigh the downside, because tamoxifen is so successful at preventing a recurrence of common breast tumors.

Many question the report and its methodology, which is the typical reaction from the medical community to bad news. And this is especially bad news, as tamoxifen is a staple in the fight against cancer.

The report about tamoxifen was not based on a research study, but only on observation. However the observation was made at the esteemed Fred Hutchinson Cancer Research Center in Seattle, WA, a center long known for comprehensive scientific research and reporting. The report was published in Cancer Research. According the Dr. Li, the author of the report, long term tamoxifen usage increases risk by four-fold for a more aggressive, difficult-to-treat type of cancer in the breast opposite, or contralateral, to the initial tumor.

This report follows previously published findings by Dr. Li in 2001, in which the same findings were reported. At that time, Dr. Li found a fivefold increased risk of estrogen-receptor (ER)-negative breast cancers in breast cancer survivors taking tamoxifen. The 2001 study contained 9,000 women over the age of 50. They were followed from 1990 and 1999. All of the women lived in Western Washington State and this study was the first population-based study that looked at the estrogen-receptors in contralateral (opposite side of the body) breast tumors.

The use of tamoxifen has been shown to reduce by 20% the ER-positive contralateral breast cancers - the most common type. This type of cancer is found in two-thirds of the cases diagnosed. Now that findings show a 500% increase in of estrogen-receptor (ER)-negative breast cancers, breast cancer survivors and their caregivers should assess the risks versus benefits and perhaps seek alternative treatments.

New research in the area of homeopathy and botanical medicine shows promise for both cancer prevention and cancer relapse, without the side effects known to be triggered by tamoxifen and other drugs. It is hoped that research in these fields will fill the need for cancer prevention in coming years.

About the author

Melanie Grimes is a writer, award-winning screenwriter, medical journal editor, and adjunct faculty member at Bastyr University. She also teaches homeopathy at the Seattle School of Homeopathy and the American Homeopathic Medical College.
A trained homeopath, she is the editor of the homeopathic journal, Simillimum, and has edited alternative and integrative medical journals for 15 years. She has taught creative writing, founded the first Birkenstock store in the USA and authored medical textbooks.
Her ebook on Natural Remedies for the Flu is available at:
Follow her blog at

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...


Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of, the internet's No. 1 natural health news site. (Source:

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.